180 related articles for article (PubMed ID: 8396699)
1. Efficacy of vitamin D3 derivatives in the treatment of psoriasis vulgaris: a preliminary report.
el-Azhary RA; Peters MS; Pittelkow MR; Kao PC; Muller SA
Mayo Clin Proc; 1993 Sep; 68(9):835-41. PubMed ID: 8396699
[TBL] [Abstract][Full Text] [Related]
2. Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study.
Durakovic C; Malabanan A; Holick MF
Br J Dermatol; 2001 Mar; 144(3):500-6. PubMed ID: 11260006
[TBL] [Abstract][Full Text] [Related]
3. Treatment of psoriasis with calcipotriol and other vitamin D analogues.
Kragballe K
J Am Acad Dermatol; 1992 Dec; 27(6 Pt 1):1001-8. PubMed ID: 1479078
[TBL] [Abstract][Full Text] [Related]
4. Psoriasis treatment with vitamin D derivatives.
Menné T; Larsen K
Semin Dermatol; 1992 Dec; 11(4):278-83. PubMed ID: 1337262
[TBL] [Abstract][Full Text] [Related]
5. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
Guzzo C; Lazarus G; Goffe BS; Katz HI; Lowe NJ; Pincus SH
J Am Acad Dermatol; 1996 Mar; 34(3):429-33. PubMed ID: 8609254
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3 analogues.
Kragballe K
Dermatol Clin; 1995 Oct; 13(4):835-9. PubMed ID: 8785887
[TBL] [Abstract][Full Text] [Related]
7. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions.
Kang S; Yi S; Griffiths CE; Fancher L; Hamilton TA; Choi JH
Br J Dermatol; 1998 Jan; 138(1):77-83. PubMed ID: 9536226
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis.
Pèrez A; Chen TC; Turner A; Raab R; Bhawan J; Poche P; Holick MF
Br J Dermatol; 1996 Feb; 134(2):238-46. PubMed ID: 8746336
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
[TBL] [Abstract][Full Text] [Related]
10. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
13. Oral calcium tolerance test in extensive psoriasis treated with topical calcipotriol.
Gumowski-Sunek D; Rizzoli R; Saurat JH
Dermatology; 1995; 190(1):43-7. PubMed ID: 7894096
[TBL] [Abstract][Full Text] [Related]
14. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
Highton A; Quell J
J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the 20-epi-vitamin D3 analogue KH 1060 in the topical therapy of psoriasis: results of a dose-ranging study.
Kragballe K; Dam TN; Hansen ER; Baadsgaard O; Grønhøj Larsen F; Søndergaard J; Axelsen MB
Acta Derm Venereol; 1994 Sep; 74(5):398-402. PubMed ID: 7817684
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis and vitamin D3. A review of our experience.
Morimoto S; Yoshikawa K
Arch Dermatol; 1989 Feb; 125(2):231-4. PubMed ID: 2536537
[TBL] [Abstract][Full Text] [Related]
18. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
Silver S; Tuppal R; Gupta AK; Clonier F; Olesen M; Leeder R; Taraska V
J Drugs Dermatol; 2013 Aug; 12(8):882-7. PubMed ID: 23986161
[TBL] [Abstract][Full Text] [Related]
19. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
[TBL] [Abstract][Full Text] [Related]
20. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
Tirado-Sánchez A; Ponce-Olivera RM
Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
